Heartflow (NASDAQ:HTFL) Major Shareholder Bain Capital Life Sciences Inv Sells 948,757 Shares

Key Points

• Bain Capital Life Sciences sold 948,757 shares of HeartFlow on April 30 at an average price of $29.23 (≈$27.7M), part of a series of recent disposals (including 797,133 on Apr 29, 254,110 on Apr 28 and 2,000,000 on Feb 4) that reduced its stake by 10.10%.
• HeartFlow shares traded around $29.76 with a market cap of about $2.55 billion, and analysts hold a consensus rating of “Moderate Buy” with an average target price of $37.67.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the business's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total value of $27,732,167.11. Following the sale, the insider owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. The trade was a 10.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Bain Capital Life Sciences Inv also recently made the following trade(s):

• On Wednesday, April 29th, Bain Capital Life Sciences Inv sold 797,133 shares of Heartflow stock. The stock was sold at an average price of $29.37, for a total value of $23,411,796.21.
• On Tuesday, April 28th, Bain Capital Life Sciences Inv sold 254,110 shares of Heartflow stock. The shares were sold at an average price of $30.51, for a total value of $7,752,896.10.
• On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00.

Heartflow Price Performance

NASDAQ:HTFL traded up $0.23 during trading hours on Thursday, reaching $29.76. 1,494,251 shares of the company traded hands, compared to its average volume of 1,071,590. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The firm's 50-day moving average is $26.11 and its 200-day moving average is $29.28. The stock has a market cap of $2.55 billion and a P/E ratio of -14.95.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Canaccord Genuity Group raised their price objective on Heartflow from $40.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, March 19th. JPMorgan Chase & Co. cut their price objective on Heartflow from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, March 19th. Finally, Wells Fargo & Company dropped their target price on Heartflow from $38.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, March 19th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.67.

Hedge Funds Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently bought and sold shares of HTFL. Caitong International Asset Management Co. Ltd acquired a new position in Heartflow in the fourth quarter valued at approximately $27,000. TFC Financial Management Inc. acquired a new position in Heartflow in the third quarter valued at approximately $40,000. Russell Investments Group Ltd. acquired a new position in Heartflow in the fourth quarter valued at approximately $45,000. Legal & General Group Plc acquired a new position in Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new position in shares of Heartflow during the fourth quarter worth approximately $99,000.

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.